Investigation of possible endogenous hypoxia markers in colorectal cancer

International Journal of Radiation Biology

Volumn 89, Issue 1, 2013, Pages 9-15

  Verstraete, Maud ^a   Debucquoy, Annelies ^a   Devos, Ellen ^a   Sagaert, Xavier ^b   Penninckx, Freddy ^c   Begg, Adrian ^d   Haustermans, Karin ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UH Gasthuisberg ^*  (Belgium)

^c Abdominal Transplant Surgery   (Belgium)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Colorectal cancer; Hypoxia; Intrinsic markers

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; PIMONIDAZOLE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYLHYDROXYLASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; COLORECTAL NEOPLASMS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; NITROIMIDAZOLES; PROCOLLAGEN-PROLINE DIOXYGENASE; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871853433     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2012.715789     Document Type: Article

References (20)

1. Brown JM, Le QT. 2002. Tumor hypoxia is important in radiotherapy, but how should we measure it? International Journal of Radiation Oncology Biology Physics 54: 1299-1301.
2. Bussink J, Kaanders JH, van der Kogel AJ. 2003. Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiotherapy and Oncology 67: 3-15.
3. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, Wileyto EP, Jenkins K, Hahn SM, Stevens CW, Judkins AR, Phillips P, Geoerger B, Koch CJ. 2004. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Research 64: 1886-1892.
4. Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F. 2001. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 60: 162-169.
5. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De SH, Penninckx F, McBride WH, Begg AC, Haustermans KM. 2006. Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers. International Journal of Radiation Oncology Biology Physics 65: 246-254.
6. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE. 1998. GLUT1 glucose transporter expression in colorectal carcinoma: A marker for poor prognosis. Cancer 83: 34-40.
7. Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. 2007. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Laboratory Investigation 87: 1206-1217.
8. Janssen HL, Haustermans KM, Balm AJ, Begg AC. 2005. Hypoxia in head and neck cancer: How much, how important? Head and Neck 27: 622-638.
9. Jiang BH, Semenza GL, Bauer C, Marti HH. 1996. Hypoxiainducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. American Journal of Physiology 271: C1172-1180.
10. Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, Ladekarl M, Havsteen H, Lindegaard JC, Davidson SE, Varia M, West C, Hunter R, Overgaard J, Raleigh JA. 2003. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiotherapy and Oncology 67: 35-44.
11. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F. 2008. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Archiv 452: 139-146.
12. Potter C, Harris AL. 2004. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3: 164-167.
13. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW. 2008. Targeting lactatefueled respiration selectively kills hypoxic tumor cells in mice. Journal of Clinical Investigation 118: 3930-3942.
14. Sorensen BS, Alsner J, Overgaard J, Horsman MR. 2007. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiotherapy and Oncology 83: 362-366.
15. Tredan O, Galmarini CM, Patel K, Tannock IF. 2007. Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 99: 1441-1454.
16. Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, van der Kogel AJ, Boerman OC, Bussink J. 2006. Imaging hypoxia after oxygenation-modification: Comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiotherapy and Oncology 80: 157-164.
17. Varghese AJ, Gulyas S, Mohindra JK. 1976. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Research 36: 3761-3765.
18. Vaupel P, Mayer A. 2007. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer and Metastasis Reviews 26: 225-239.
19. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. 2011. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Research 71: 2550-2560.
20. Xue J, Li X, Jiao S, Wei Y, Wu G., Fang J. 2010. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 138: 606-615.